Efficacy and Toxicity of Two Doses of Trimethoprim-Sulfamethoxazole as Primary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with Human Immunodeficiency Virus

Efficacy and Toxicity of Two Doses of Trimethoprim-Sulfamethoxazole as Primary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with Human Immunodeficiency Virus

The efficacy and toxicity of trimethoprim-sulfamethoxazole (TMP-SMZ) as primary prophylaxis against Pneumocystis carinii pneumonia (PCP) for patients with human immunodeficiency virus (HIV) infection was assessed by comparing the effects of two dosages (480 or 960 mg once a day) of the drug. The mul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 1995-06, Vol.171 (6), p.1632-1636
Hauptverfasser: Schneider, Margriet M. E., Nielsen, Thyge L., Nelsing, Suzanne, Hoepelman, Andy I. M., Schattenkerk, Jan Karel M. Eeftinck, van der Graaf, Yolanda, Kolsters, Ad F. P., Borleffs, Jan C. C.
Format: Artikel
Sprache:eng
Schlagworte:
Adverse drug reactions
AIDS
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Cerebral toxoplasmosis
Concise Communications
Dosage
Experimentation
HIV
human immunodeficiency virus
Infectious diseases
Medical sciences
Pharmacology. Drug treatments
Pneumocystis carinii
Pneumocystis pneumonia
Preventive medicine
University hospitals
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The efficacy and toxicity of trimethoprim-sulfamethoxazole (TMP-SMZ) as primary prophylaxis against Pneumocystis carinii pneumonia (PCP) for patients with human immunodeficiency virus (HIV) infection was assessed by comparing the effects of two dosages (480 or 960 mg once a day) of the drug. The multicenter trial involved 260 HIV-infected patients with CD4 cell counts
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/171.6.1632